Disruptive Anti-Infective Technologies

ContraFect is developing first-in-class therapies for drug resistant, life threatening infections.

News & Events See All News & Events ?

Jun 17, 2019

ContraFect Announces ASM Microbe 2019 Outstanding Abstract Award and Presentation of New Data

Read More ?

Press Coverage

Lysin Plus Antibiotics: A Cure for Human Bacterial Infections?

Reuters

View »

About

ContraFect is a clinical-stage biotechnology company focused on discovering and developing biologic therapies for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. We intend to address life threatening infections using our therapeutic product candidates from our platform of direct lytic agents (DLAs), which include lysins and amurin peptides. We believe DLAs provide the opportunity to make meaningful improvements to clinical outcomes and to change the treatment paradigm for patients infected with antibiotic-resistant bacteria. Our initial product candidates are new agents to treat lethal, resistant infections such as methicillin-resistant Staph aureus (MRSA) and Gram-negative pathogens like multi-drug resistant (MDR) Pseudomonas aeruginosa.


Learn More ?

Leadership

Our leadership team has a track record of creating shareholder value.

Roger J. Pomerantz, M.D., F.A.C.P.

Roger J. Pomerantz, M.D., F.A.C.P.

President, Chief Executive Officer and Chairman of the Board

Dr. Pomerantz was appointed ContraFect’s President, Chief Executive Officer and Chairman of the board of directors in April of 2019, prior to which he served as Vice Chairman of the Company’s board of directors sinc...

View Full Profile ?
Cara Cassino, M.D.

Cara Cassino, M.D.

Chief Medical Officer and Executive Vice President of Research and Development

Dr. Cassino has over 20 years of experience as a clinician and executive in healthcare, including over 14 years of experience in pharmaceutical product development and over 20 successful regulatory submissions in the US and glo...

View Full Profile ?
Michael Messinger, CPA

Michael Messinger, CPA

Chief Financial Officer

Mr. Messinger has more than 15 years of experience in finance, accounting and forecasting for clinical development. He served as Controller of Coelacanth Corporation prior to his role as Director of Finance for Lexicon Pharmace...

View Full Profile
Nancy Dong

Nancy Dong

VP, Finance & Administration

Ms. Dong has more than 20 years of experience in accounting, strategic planning, budgeting and forecasting, organizational development, financial systems and controls. She served as controller at XL Marketing and Alley Corp pri...

View Full Profile
Natalie Bogdanos

Natalie Bogdanos

General Counsel, Corporate Secretary & Data Protection Officer

Ms. Bogdanos has more than 20 years of in-depth legal experience, across many areas of law including contract, intellectual property, licensing, regulatory, corporate governance, securities, litigation and data privacy. 14 of t...

View Full Profile
Roger J. Pomerantz, M.D., F.A.C.P.

Roger J. Pomerantz, M.D., F.A.C.P.

President, Chief Executive Officer and Chairman of the Board

Dr. Pomerantz was appointed ContraFect’s President, Chief Executive Officer and Chairman of the board of directors in April of 2019, prior to which he served as Vice Chairman of the Company’s board of directors sinc...

View Full Profile
Sol Barer, Ph.D.

Sol Barer, Ph.D.

Lead Director

Dr. Barer joined Celanese Research Company in 1974 and formed the Biotechnology Group that was spun out to form Celgene. Dr. Barer was Chairman and Chief Executive Officer from May 1, 2006 until June 16, 2010 and served as Exec...

View Full Profile
Steven C. Gilman, Ph.D.

Steven C. Gilman, Ph.D.

Vice Chairman of the Board

Dr. Gilman has served on the board of directors since May 2015. He was Chief Executive Officer and Chairman of the board of directors from May 2015 until April 2019. Prior to ContraFect, he served as the Executive Vice Presiden...

View Full Profile
Cary W. Sucoff

Cary W. Sucoff

Director

Mr. Sucoff has served as a member of our board of directors since May 2010. Mr. Sucoff has more than 30 years of securities industry experience encompassing supervisory, banking and sales responsibilities. He has participated i...

View Full Profile
David N. Low, Jr.

David N. Low, Jr.

Director

Mr. Low has served as a member of our board of directors since April 2014. Mr. Low has worked as an investment banker since 1987, with broad investment and advisory experience in the life sciences, biotechnology and medical tec...

View Full Profile
Michael J. Otto, Ph.D.

Michael J. Otto, Ph.D.

Director

Dr. Otto has served as a member of our board of directors since April 2014. Most recently, he was Chief Scientific Officer of Pharmasset from October 1999 until February 2012, when the company was acquired by Gilead Sciences. H...

View Full Profile

Stock Information Data is 15 minutes delayed

ContraFect Corporation — Common Stock Nasdaq: CFRX
Price
Change
Market Cap
Volume
View Our

SEC Filings